Recce Pharmaceuticals Advances Diabetic Foot Infection Trial to Pivotal Phase 3 in Australia-Indonesia

The Quick Take

• Recce Pharmaceuticals advanced its diabetic foot infection treatment to a pivotal Phase 3 trial with broadened recruitment criteria.
• The trial expansion adds below-knee ulcers to eligibility criteria and operates across a dual Australia-Indonesia program.
• The Phase 3 advancement validates Recce's synthetic antibiotic in a high-unmet-need diabetic wound care indication.

Recce Pharmaceuticals, an Australian biotech developing synthetic antibiotics for drug-resistant infections, advanced its diabetic foot infection treatment program to a pivotal Phase 3 trial, representing a critical de-risking event for the small-cap company. The trial expansion broadens patient eligibility by adding below-knee ulcers as a qualifying condition, and extends the program across a dual Australia-Indonesia protocol — reflecting the company's strategy to recruit patients from populations with high diabetic foot infection prevalence. Phase 3 designation as a pivotal study means this trial is designed to generate regulatory submission-grade efficacy and safety data.

Diabetic foot infection represents one of the largest unmet needs in antimicrobial medicine, with drug-resistant organisms increasingly defeating conventional antibiotic regimens and driving hospitalizations, amputations, and mortality in diabetic populations. For Recce Pharmaceuticals — listed on the ASX — the Phase 3 advancement is a share price catalyst that confirms the company has sufficient clinical and financial runway to pursue regulatory approval without further de-risking delays. Larger pharma companies including Pfizer, MSD, and Melinta Therapeutics have maintained active interest in acquiring late-stage antibiotic assets, given the high attrition rates in infectious disease drug development that make in-licensing of Phase 3 assets commercially rational.

The critical forward signal is the Phase 3 trial's interim safety and efficacy readout, which should provide the first signal on whether Recce's synthetic antibiotic maintains its Phase 2 efficacy profile at scale. Watch for WHO and Australian TGA guidance on accelerated approval pathways for novel antibiotics addressing drug-resistant organisms, as policy tailwinds could shorten Recce's time to market. The macro variable is the global antimicrobial resistance policy environment: increasing regulatory and reimbursement support for novel antibiotic mechanisms — including from PASTEUR Act frameworks — directly affects the commercial valuation of late-stage antibiotic assets.

Synthesized from 1 source.